
Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks Patrick Yong,¹ Tariq El-Shanawany,² Padmalal Gurugama,³ Rashmi Jain,⁴ Sherry Danese,⁵ Julie Ulloa,⁵ Vibha Desai, ⁶ Paul Audhya,⁶ Sinisa Savic⁷

¹Frimley Health NHS Foundation Trust, Frimley, United Kingdom; ²Department of Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes, United Kingdom; ⁴Clinical Immunology, Oxford University Hospital Trust, Oxford, United States; ⁷ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Department of Allergy and Clinical Immunology, St James's University Hospital NHS Trust, Leeds, United Kingdom.


Hereditary angloodoma (UAE) is characterized by					
 Hereditary angioedema (HAE) is characterized by unpredictable swelling attacks affecting cutaneous and submucosal tissues, which are typically painful, 	Table 1. Respondent Characteristics Characteristic	Total (N=46 Adults)	On-Demand (n=21, 46%		LTP On-Dem (n=25, 5
debilitating, and potentially fatal	Current Age (Mean)	44 years	42 years		46 yea
WAO/EAACI 2021 updated guidelines recommend the orly use of on demond treatment following attack	Age of Diagnosis (Mean)	17 years	17 years		17 yea
early use of on-demand treatment following attack recognition to reduce morbidity and prevent mortality ¹⁻³	Gender				
	Male Female	28% 70%	33% 67%		24% 72%
All currently approved on-demand treatment options require parenteral administration, which can be	Prefer not to respond	2%	-		4%
challenging to administer, resulting in anxiety and	Race / Ethnicity	040/	05%		0.00/
increased treatment burden ⁴	White Black / Black British / Caribbean or	91%	95%		88% —
	African Asian or Asian British	7%	5%		8%
Objective	Other	_	_		-
The current study aimed to characterize anxiety related	Prefer not to respond	2%	_		4%
to use of parenteral on-demand therapy for HAE	HAE Type Type I	100%	100%		100%
attacks administered either subcutaneously (SC) or	Type II	_	-		-
intravenously (IV)	Time Since Last Treated Attack (Mean)	16 days	13 days		18 da <u>y</u>
Methods	Figure 1. On-Demand Treatment administered for the last treated attack*		2. Long-Term Pro of last treated attack	ophylaxis	
Participants with Type 1 or 2 HAE were recruited through HAE UK, the patient organization, between April and May 2023	Icatibant 50.0%	esterase			1.7%
 Recruitment was stratified to include 50% of participants taking on-demand only and 50% receiving long-term prophylaxis (LTP) + on-demand 	Cinryze 15.2%		adelumab erotralstat 6.	13.0% 5%	
The survey was self-reported, and took respondents approximately 20 minutes to complete	Ruconest 4.3%		Danazol 6.	5%	
Study population included participants that were at	0% 20% 40% 60%	% 80% Trane>	amic acid 6.	5%	
ast 18 years of age, had at least one HAE attack thin the three months prior to the survey and had eated that attack with an approved on-demand	*3 respondents that treated this attack with icatibant second dose of the same treatment when initial sym improve after first dose		0%	20%	
therapy	Table 2. Reported Level of Anxiety A	ssociated with Treating	g Most Recent Att	ack	
Respondents provided consent for their data to be used anonymously or in aggregate	Level of Anxiety	Total (N=46) On-Deman Only (n=21)	d LTP + On-Demand (n=25)	SC (n=23)	(r
Anxiety was rated on a scale of 0 (not at all anxious),	Not Anxious (0 on scale of 0-10)	11 (23.9%) 7 (33.3%)	4 (16.0%)	7 (30.4%)	4 (*
1-3 (mildly anxious), 4-6 (moderately anxious) and 7-		14 (30.4%) 6 (28.6%)	. ,	8 (34.8%)	6 (2
10 (extremely anxious)	Moderately Anxious (4-6 on scale of 0-10) Extremely Anxious (7-10 on scale of 0-10)	6 (13.0%)3 (14.3%)15 (32.6%)5 (23.8%)	3 (12.0%) 10 (40.0%)	4 (17.4%) 4 (17.4%)	2 (11 (
Analysis was performed using descriptive statistics	Respondents were asked, "How much anxiety did yo	u feel about treating this HAE a	· · · · · ·	· · · /	,
	to select from 0-Not at all anxious to 10-Extremely an	IXIOUS			
CES S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline. <i>Allergy,</i> mmunology. 2019/11/25 2019;15(1):72. doi:10.1186/s13223-019-0376-8 J, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Mana y Angioedema. <i>The journal of allergy and clinical immunology In practice</i> . Jan 2021;9(1):132-150.e3 16/j.jaip.2020.08.046	presented and provided final appr gement of Patrick Yong - Consulting fees, ho	oval of all content. Neither hon onoraria and/or support for atter , research support, speaker fee	oraria nor payments we nding meetings from Ast es and/or consultant fee	re made for aut tria, Biocryst, C es from ALK-Ab	ithorship. CSL Behri pello, Aller

- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary
- angioedema-The 2021 revision and update. Allergy. Jul 2022;77(7):1961-1990. doi:10.1111/all.15214 4. Burnette A, et al. Anxiety Associated With Parenteral On-demand Treatment For Hereditary Angioedema (HAE). J Allergy Clin Immunol. 2023 Feb;151(2):AB141



nd had full access to relevant data. The authors had full editorial control of the data ehring, KalVista Pharmaceuticals, Inc., Pharming, Pharvaris and Takeda; Tariq El-Allergy Therapeutics, CSL, KalVista Pharmaceuticals, Inc., Octapharma, Novartis, Advisory board for KalVista Pharmaceuticals, Inc.; Sherry Danese - Consultant fees from KalVista Pharmaceuticals, Inc.; Julie Ulloa - Consultant fees from KalVista Pharmaceuticals, Inc.; Vibha Desai and Paul Audhya - Employees of KalVista Pharmaceuticals, Inc.; Sinisa Savic - Consulting fees and/or honoraria from CSL Behring, Biocryst, KalVista Pharmaceuticals, Inc, Pharvaris, Novartis, and Astra Zeneca

Results



Presented: 2024 EAACI Conference, May 31 – June 3, 2024 in Valencia, Spain

Scan this QR code to view the poster after the congress.

		<i>,</i>		SC	IV
			0 ((n=16)	(n=19)
		40.0	%	43.8%	36.8%
	05 70/	37.1%		50.0%	26.3%
	25.7%				47.4%
20.0%)			25.0%	15.8%
17.1%				12.5%	21.1%
17.1%				18.8%	15.8%
14.3%				6.3%	26.3%
14.3%				12.5% 18.8%	15.8% 10.5%
14.3%					
4%				25.0% 25.0%	5.3%
4%				18.8%	 5.3%
4%				12.5%	10.5%
				6.3%	10.5%
				6.3%	5.3%
20%	30%	40%	50%		
	oondent	s' Report Mean rep	ported t n to on-	tiety Level time from at demand tre 5 hours	ttack
ing to Resp	oondent r	s' Report Mean rep ecognitior	ported t n to on- was 4.6	time from at demand tre	ttack atment
ing to Resp	oondent	s' Report Mean rep ecognitior	ported t n to on- was 4.6	time from at demand tre 6 hours	ttack atment
	oondent r 0.0% Extrer Mode Mildly	s' Report Mean rep ecognition (SC: 2.4 mely Anxious rately Anxious	ported to n to on- was 4.6 5 hours s (7-10 o us (4-6 o 3 on sca	n scale of 0-1 n scale of 0-1 n scale of 0-1	ttack atment urs) 0) n=15 0) n=6
ing to Resp 5 46.7% 45.5%	oondent r 0.0% Extrer Mode Mildly Not A	s' Report Mean rep ecognition (SC: 2.4 mely Anxious rately Anxious Anxious (1- nxious (0 on 60%	ported to n to on- was 4.6 5 hours s (7-10 o us (4-6 o 3 on sca n scale of	n scale of 0-1 n scale of 0-1 n scale of 0-1	ttack atment urs) 0) n=15 0) n=6
ing to Resp 5 46.7% 45.5%	oondent r 0.0% Extrer Mode Mildly Not A	s' Report Mean rep ecognition (SC: 2.4 mely Anxious rately Anxious Anxious (1- nxious (0 on 60%	ported to n to on- was 4.6 5 hours s (7-10 o us (4-6 o 3 on sca n scale of	n scale of 0-1 n scale of 0-1 n scale of 0-1 n scale of 0-1	ttack atment Irs) 0) n=15 0) n=6 14
ang to Resp 5 46.7% 45.5%	oondent r 0.0% Extrer Mode Mildly Not A	s' Report Mean rep ecognition (SC: 2.4 mely Anxious rately Anxious Anxious (1- nxious (0 on 60%	ported to n to on- was 4.6 5 hours s (7-10 o us (4-6 o 3 on sca n scale of	n scale of 0-1 n scale of 0-1 n scale of 0-1 n scale of 0-1	ttack atment Irs) 0) n=15 0) n=6 14
ng to Resp 5 46.7% 45.5%	oondent r 0.0% Extrer Mode Mildly Not A	s' Report Mean rep ecognition (SC: 2.4 mely Anxious rately Anxious Anxious (1- nxious (0 on 60%	ported to n to on- was 4.6 5 hours s (7-10 o us (4-6 o 3 on sca n scale of	n scale of 0-1 n scale of 0-1 n scale of 0-1 n scale of 0-1	ttack atment Irs) 0) n=15 0) n=6 14

